Collaboration, License, and Other Agreements - Checkmate Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Acquired in-process research and development in connection with asset acquisition	$ 0.0	$ 195.0	$ 0.0
Asset acquisition, cash and equivalents		26.4
Checkmate Pharmaceuticals, Inc.
Disaggregation of Revenue [Line Items]
Asset acquisition, consideration transferred		250.0
Acquired in-process research and development in connection with asset acquisition		195.0
Asset acquisition, assets acquired and liabilities assumed, net		$ 61.7